Janux Therapeutics (NASDAQ:JANX) Stock Price Down 6.6%

Janux Therapeutics, Inc. (NASDAQ:JANXGet Rating) shares were down 6.6% on Friday . The stock traded as low as $14.48 and last traded at $14.74. Approximately 1,241 shares changed hands during mid-day trading, a decline of 99% from the average daily volume of 103,848 shares. The stock had previously closed at $15.79.

Analyst Upgrades and Downgrades

Separately, William Blair started coverage on Janux Therapeutics in a research report on Monday, November 14th. They issued an “outperform” rating for the company.

Janux Therapeutics Stock Down 7.8 %

The company has a market capitalization of $606.57 million, a P/E ratio of -9.97 and a beta of 1.33. The firm has a 50-day moving average price of $14.98 and a two-hundred day moving average price of $13.22.

Institutional Trading of Janux Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in JANX. Amalgamated Bank acquired a new stake in Janux Therapeutics in the first quarter worth about $28,000. Parkwood LLC increased its position in Janux Therapeutics by 19.4% in the second quarter. Parkwood LLC now owns 33,750 shares of the company’s stock worth $34,000 after purchasing an additional 5,492 shares during the period. BNP Paribas Arbitrage SNC bought a new position in Janux Therapeutics during the third quarter worth about $103,000. American International Group Inc. boosted its holdings in Janux Therapeutics by 25.3% during the first quarter. American International Group Inc. now owns 8,813 shares of the company’s stock worth $126,000 after buying an additional 1,782 shares during the last quarter. Finally, MetLife Investment Management LLC boosted its holdings in Janux Therapeutics by 100.2% during the first quarter. MetLife Investment Management LLC now owns 10,614 shares of the company’s stock worth $152,000 after buying an additional 5,312 shares during the last quarter. 69.40% of the stock is currently owned by institutional investors and hedge funds.

About Janux Therapeutics

(Get Rating)

Janux Therapeutics, Inc, a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2.

Read More

Receive News & Ratings for Janux Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Janux Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.